Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Rating) major shareholder David Soane purchased 202,701 shares of the business's stock in a transaction dated Wednesday, January 4th. The shares were purchased at an average price of $1.23 per share, with a total value of $249,322.23. Following the purchase, the insider now directly owns 3,336,562 shares in the company, valued at approximately $4,103,971.26. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

David Soane also recently made the following trade(s):

• On Tuesday, November 8th, David Soane purchased 3,000 shares of Comera Life Sciences stock. The shares were purchased at an average price of $1.38 per share, with a total value of $4,140.00.

Comera Life Sciences Trading Up 24.2 %

CMRA stock opened at $1.52 on Friday. Comera Life Sciences Holdings, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $11.44. The stock has a fifty day moving average of $1.37 and a 200-day moving average of $1.96.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in Comera Life Sciences in the 2nd quarter worth about $115,000. Lake Street Advisors Group LLC boosted its stake in Comera Life Sciences by 216.5% in the 3rd quarter. Lake Street Advisors Group LLC now owns 316,469 shares of the company's stock worth $510,000 after purchasing an additional 216,469 shares during the period. Virtu Financial LLC bought a new position in Comera Life Sciences in the 3rd quarter worth about $25,000. Arena Investors LP bought a new position in Comera Life Sciences in the 3rd quarter worth about $137,000. Finally, Bluefin Capital Management LLC bought a new position in Comera Life Sciences in the 2nd quarter worth about $73,000. Institutional investors own 2.94% of the company's stock.

Comera Life Sciences Company Profile

(Get Rating)

Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.

See Also

• Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRA)
• MarketBeat: Week in Review 01/02-01/06
• Why is the CrowdStrike Stock Price Struggling?
• Four Undervalued Healthcare Stocks for 2023
• WWE Stock: Vince McMahon Wants Back In The Show
• NVIDIA Is Bottoming But Don't Buy It Just Yet

Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.